Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1401423-31-1

5-Methoxy-2-methyl-4-nitrobenzoic acid is an organic compound characterized by its molecular formula C9H9NO5. 5-methoxy-2-methyl-4-nitrobenzoic acid features a benzoic acid structure with a methyl group at the 2nd carbon, a methoxy group at the 5th carbon, and a nitro group at the 4th carbon. It is a yellow crystalline solid with a melting point of approximately 180-182°C. This chemical is known for its potential applications in the synthesis of pharmaceuticals and other organic compounds, particularly those with analgesic or anti-inflammatory properties. Due to its reactivity and functional groups, it can undergo various chemical reactions, making it a versatile intermediate in organic synthesis.

1401423-31-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1401423-31-1 Structure

  • Basic information

    1. Product Name: 5-methoxy-2-methyl-4-nitrobenzoic acid
    2. Synonyms: 5-methoxy-2-methyl-4-nitrobenzoic acid
    3. CAS NO:1401423-31-1
    4. Molecular Formula:
    5. Molecular Weight: 211.174
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1401423-31-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 5-methoxy-2-methyl-4-nitrobenzoic acid(CAS DataBase Reference)
    10. NIST Chemistry Reference: 5-methoxy-2-methyl-4-nitrobenzoic acid(1401423-31-1)
    11. EPA Substance Registry System: 5-methoxy-2-methyl-4-nitrobenzoic acid(1401423-31-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1401423-31-1(Hazardous Substances Data)

1401423-31-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1401423-31-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,1,4,2 and 3 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1401423-31:
(9*1)+(8*4)+(7*0)+(6*1)+(5*4)+(4*2)+(3*3)+(2*3)+(1*1)=91
91 % 10 = 1
So 1401423-31-1 is a valid CAS Registry Number.

1401423-31-1Relevant articles and documents

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

-

Page/Page column 96, (2014/07/08)

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

-

Page/Page column 62; 63, (2013/06/27)

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS

-

Page/Page column 50-51, (2013/06/27)

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for t

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors

Estrada, Anthony A.,Liu, Xingrong,Baker-Glenn, Charles,Beresford, Alan,Burdick, Daniel J.,Chambers, Mark,Chan, Bryan K.,Chen, Huifen,Ding, Xiao,Dipasquale, Antonio G.,Dominguez, Sara L.,Dotson, Jennafer,Drummond, Jason,Flagella, Michael,Flynn, Sean,Fuji, Reina,Gill, Andrew,Gunzner-Toste, Janet,Harris, Seth F.,Heffron, Timothy P.,Kleinheinz, Tracy,Lee, Donna W.,Le Pichon, Claire E.,Lyssikatos, Joseph P.,Medhurst, Andrew D.,Moffat, John G.,Mukund, Susmith,Nash, Kevin,Scearce-Levie, Kimberly,Sheng, Zejuan,Shore, Daniel G.,Tran, Thuy,Trivedi, Naimisha,Wang, Shumei,Zhang, Shuo,Zhang, Xiaolin,Zhao, Guiling,Zhu, Haitao,Sweeney, Zachary K.

, p. 9416 - 9433 (2013/01/16)

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1401423-31-1